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What’s already known?  
• Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) and 
Xeroderma pigmentosum complementation group C (XPC) are three genodermatoses 
with high predisposition to cancer development. 
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• Although their causal genetic mutations mainly affect epithelia, the dermal 
microenvironment likely contributes to the physiopathology of these disorders. 
What does this study add? 
• We disclose a large gene transcription overlapping profile between XPC, KS and 
RDEB fibroblasts that point towards an activated phenotype with high matrix-
synthetic capacity. 
• This common signature seems to be independent of the primary causal deficiency, but 
reflects an underlying derangement of the extracellular matrix via TGF-β signalling 
activation and oxidative state imbalance. 
What is the translational message? 
• This study broadens the current knowledge about the pathology of these diseases and 
highlights new targets and biomarkers for effective therapeutic intervention. 
• It is suggested that high levels of circulating periostin could represent a potential 
biomarker in RDEB. 
 
Summary 
Background: Recessive dystrophic epidermolysis bullosa (RDEB), Kindler syndrome (KS) 
and Xeroderma pigmentosum C (XPC) are three cancer-prone genodermatoses whose causal 
genetic mutations cannot fully explain, on their own, the array of associated phenotypic 
manifestations. Recent evidence highlights the role of the stromal microenvironment in the 
pathology of these disorders. 
Objectives: To investigate, by means of comparative gene expression analysis, the role 
played by dermal fibroblasts in the pathogenesis of RDEB, KS and XPC. 
Methods: We conducted RNA-Seq analysis that included a thorough examination of the 
differentially expressed genes, a functional enrichment analysis and a description of affected 
signalling circuits. Transcriptomic data were validated at the protein level in cell cultures, 
serum samples and skin biopsies.  
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Results: Inter-disease comparisons against control fibroblasts revealed a unifying signature of 
186 differentially expressed genes and 4 signalling pathways in the three genodermatoses. 
Remarkably, some of the uncovered expression changes suggest a synthetic fibroblast 
phenotype characterized by the aberrant expression of extracellular matrix (ECM) proteins. 
Western blot and immunofluorescence in situ analysis validated the RNA-Seq data. In 
addition, enzyme-linked immunosorbent assay (ELISA) revealed increased circulating levels 
of periostin in RDEB patients. 
Conclusions: Our results suggest that the different causal genetic defects converge into 
common changes in gene expression, possibly due to injury-sensitive events. These, in turn, 
trigger a cascade of reactions involving the abnormal ECM deposition and under-expression 
of antioxidant enzymes. The elucidated expression signature provides new potential 
biomarkers and common therapeutic targets in RDEB, XPC and KS. 
 
Keywords: dystrophic epidermolysis bullosa, xeroderma pigmentosum, Kindler syndrome, 
RNA-Seq, TGF-ß, oxidative stress. 
 
Introduction 
The progress made in molecular genetics has greatly contributed to identify the 
primary causes of a large number of heritable skin diseases (1). However, these findings do 
not always explain by themselves the complex phenotypic manifestations observed in cancer-
prone genodermatoses, such as Recessive dystrophic epidermolysis bullosa (RDEB), Kindler 
syndrome (KS) and Xeroderma pigmentosum complementation group C (XPC). RDEB is 
caused by loss-of-function mutations in the COL7A1 gene, which encodes type VII collagen 
anchoring fibrils (C7), structures that connect the epidermal basement membrane to the 
dermal tissue. C7 deficiency causes loss of dermo-epidermal adhesion, resulting in blister 
formation, scarring and aggressive carcinoma development (2). KS results from recessive 
mutations in the FERMT1 gene, encoding for kindlin-1. This protein mediates anchorage 
between the actin cytoskeleton and the extracellular matrix (ECM) via focal adhesions. KS is 
characterized clinically by early age acral skin blisters, photosensitivity, and high risk of 
mucocutaneous malignancies (3–5). XPC is characterized by mutations in the XPC gene, 
which cause a severe deficiency in the nucleotide excision repair pathway. XPC patients are 
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highly sensitive to UV radiation and have a very high risk of developing skin tumours in sun-
exposed areas, mostly basal and squamous cell carcinomas arising from epidermal 
keratinocytes, and malignant melanomas (6). XPC patients have also a high risk of 
developing tumours in internal organs not exposed to sunlight (7). Besides cancer 
susceptibility, other common clinical signs to the three genodermatoses are inflammation and 
premature skin aging (8–10). Although the specific primary and subsequent genetic 
alterations at the epidermal level are likely to be major drivers for carcinogenesis in these 
disorders, an altered stroma may be playing a facilitating role towards tumour development 
and malignant progression. 
Robust data, gathered mainly from omic studies of patient cells and mouse models, 
underscore the role of an aberrant extracellular matrix deposition, leading to progressive 
fibrosis and cutaneous squamous-cell carcinoma (cSCC) in RDEB. This process appears to 
be mediated by the dermal fibroblasts, that acquire molecular changes similar to those present 
in tumour microenvironment (i.e. cancer associated fibroblasts; CAFs) (11). Less is known in 
this regard for KS and XPC, although marginal evidence indicates that fibroblasts may also 
be relevant in the disease pathogenesis (12–15). Here, we demonstrate through RNA-Seq 
analysis and expression validation of relevant genes that RDEB, XPC and KS fibroblasts 
allow to establish a common pro-fibrotic microenvironment that could favour disease 
progression and cancer.  
 
Materials and methods 
Sample collection and cell culture 
All procedures were approved by the ethics committee of La Paz University Hospital 
(code HULP: PI-1602) and were conducted in accordance to the Declaration of Helsinki and 
subsequent revisions. Skin biopsies from unaffected areas of 7 healthy donors, 11 RDEB, 4 
KS, and 4 XPC patients were obtained after written informed consent. Fibroblasts were 
isolated by mechanical and enzymatic digestion as previously described (16) and cultured in 
Dulbecco’s Modified Eagle’s Medium (Gibco, Invitrogen) supplemented with 10% foetal 
bovine serum (Gibco, Invitrogen) and 1% Antibiotic-Antimycotic (Life Technologies). The 
characteristics of the patients and controls can be seen in Table S1. All cells used were at 
early 3-7 passages.  
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RNA extraction 
Culture medium was changed 24h before harvesting the cells. Total RNA was isolated 
from confluent primary fibroblasts using RNeasy kit (Qiagen, Germany) according to the 
manufacturer’s protocol recommendations. RNA concentration and quality was determined 
on a NanoDrop Spectrophotometer (Thermo Scientific) and integrity was verified with a 
Bioanalyzer 2100 (Agilent, USA). The RNA integrity number (RIN) was in all cases higher 
than 8,5. To minimize technical variability, RNA extracts from four technical replicates of 
each sample were mixed.  
 
RNA-Seq data processing 
cDNA libraries were generated for each sample using the TruSeq RNA Sample 
Preparation Kit (Illumina, CA) according to the recommended protocol. Ligation and library 
integrity was verified using an Agilent Bioanalyzer 2100. Sample libraries ligated with 
unique adapter sequences were multiplexed six to a lane and were sequenced by Edinburgh 
Genomics (Ashworth Laboratories, Scotland) using Illumina HiSeq HO v4 125 paired end 
sequencing. Quality control analysis on the resulting FASTQ files was performed using 
FastQC (Babraham Bioinformatics, UK). Reads were adapter trimmed using cutadapt version 
1.3 with the parameters -q 30 -m 50 -a AGATCGGAAGAGC. Trimmed reads were aligned 
to Ensembl version 38.81 of the Homo sapiens genome with TopHat2 version 2.0.13 using 
default parameters (except "-r -70 -mate-std-dev 75" to specify insert sizes). The BAM files 
were sorted by name using Picard-tools (version 1.115) SortSam. Read counts were generated 
using HTSeq-count version 0.6.0 in unstranded mode, and Python version 2.7.3, with 
parameters -m union -i gene_id -t exon. Raw and processed data are stored at NCBI´s Gene 
Expression Omnibus, accession code GSE119501 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE119501). 
 
RNA-Seq data were normalized using the Trimmed Mean of M values (TMM) (17). 
An adjustment for possible batch effects was performed using the R package ComBat (18). 
The transcripts that had an average expression per condition less than 1 count per million and 
a coefficient of variation per condition higher than 100% were filtered. Differential 
expression analysis was performed with the Bioconductor package edgeR (19). Conventional 
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multiple testing p-value correction procedure proposed by Benjamini–Hochberg was used to 
derive adjusted p-values (20). Enrichment analysis was carried out for the Gene Ontology 
(GO) terms using the Babelomics suite (21) as well as DAVID Bioinformatic resources (22). 
 
Pathway activity analysis and protein-protein interaction 
The signalling circuit activity analysis method (23), as implemented in the Hipathia R 
package (https://github.com/babelomics/hipathia), was applied to all disease vs healthy 
control comparisons. Under this modelling schema, signalling circuits are defined within 
KEGG pathways as the chain of proteins that connect a receptor protein to an effector protein 
that trigger specific cellular activities. The signal is propagated from the receptor protein 
along the proteins that compose the circuit by a recursive formula that takes into account the 
activity of both, activator and inhibitor proteins. Finally, the list of the common dysregulated 
genes in all disease versus controls comparisons was uploaded to STRING (24), a database 
that represents the known protein-protein interactions (PPI). The minimum required 
interaction score was set to >0.7 allowing only high confidence connections between nodes. 
 
Western Blot analysis 
Primary fibroblasts, serum-starved for 24h, were lysed with 25mM Tris-HCl (pH 7.4), 
100mM NaCl, 1% Nonidet P-40, and protease inhibitor cocktail (Roche Diagnostic). The 
extracts were cleared for cellular debris by centrifugation at 16.000g for 15min at 4°C. 
Protein extracts were electrophoresed on SDS-PAGE 4-12%Bis-Tris gel and transferred onto 
nitrocellulose membranes. The membranes were blocked with 5% non-fat milk powder in 1X 
TBS for 1h at room temperature and incubated overnight with one of the following 
antibodies: anti-Tenascin-C (MAB2138; R&D Systems), anti-βIG-H3 (D31B8; Cell 
Signaling Technology), anti-ALDH1A1 (EP1933Y; Abcam), anti-Periostin (sc-398631), anti-
Fibulin-1 (sc-25281), anti-TGase2 (sc-48387), and anti-GAPDH (sc-25778; Santa Cruz 
Biotechnology). Detection was performed using HRP-conjugated secondary antibodies and a 
chemiluminescent detection assay (SuperSignal West, Thermo Scientific). Three independent 
experiments were performed for each patient sample and controls. 
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Immunofluorescence analysis 
Skin cryo-sections from 3 healthy donors, 2 RDEB and 2 KS patients were 
immunostained against tenascin-C (MAB2138) and periostin (sc-398631). Fluorescence 
quantification was measured using the ImageJ program. A Student’s t-test was applied to 
compare the fluorescence intensity/area means of samples, using GraphPad Prism 5.04 
software (La Jolla, CA). 
 
Enzyme-linked immunosorbent assay (ELISA) 
Serum samples from 16 RDEB and 10 healthy donors (Table S1b) were analysed 
using human periostin ELISA kit (EHPOSTN-PL; Thermo Scientific) according to the 
manufacturer’s protocol. The absorbance was measured at 450nm and 550nm with a 
microtiter plate reader (TECAN Genios Pro, Austria). D’Agostino-Pearson omnibus test was 
applied to determine if the values have a normal distribution. Unpaired t-test with Welch’s 
correction was done to determine the statistical significance between RDEB and controls 
(GraphPad Prism 5.04). Two independent experiments were performed for each patient 
sample and controls. 
 
Results 
Genodermatosis patients and mutations  
Patients were screened for COL7A1, XPC and FERMT1 specific mutations, according 
to the diagnosed disease (Table S1a). All RDEB patients were homozygous for a COL7A1 
recurrent mutation (c.6527insC), leading to a premature termination codon (PTC) (25). All 
the screened XPC patients carried a homozygous frameshift mutation (c.1643_1644delTG) in 
XPC gene, resulting in PTC. Finally, KS patients were the most heterogeneous group, with 
three different homozygous mutations in FERMT1 gene. KS1 produce an altered splicing due 
to insertion of a new triplet (c.1371+4>G), KS2 is a missense variant (c.1198T>C) and KS3 
has a frameshift mutation (c.676dupC). 
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Identification of common expression signatures linked to fibroblast activation and ECM 
deposition 
RNA-Seq counts were obtained for primary fibroblasts isolated from three healthy 
donors, nine RDEB, three KS, and three XPC patients. A total of 22.970 transcripts, 
identified by their Ensembl IDs, were obtained for each sample after quality data assessment 
and normalization (Table S2). The observed arrangement of the samples in the principal 
component analysis (PCA) discarded possible batch effect and organized the samples 
following the different disease groups. Notably, all genodermatosis samples are located in 
proximity within the plot, and distinctly separated from controls (Fig. 1a), pointing towards a 
similar transcription profile between the three genodermatoses.  
In order to identify the dysregulated genes, differential expression analysis was 
carried out, contrasting each disease group (RDEB, KS or XPC) versus healthy controls 
(Table S3). The number of differentially expressed genes (FDR<0.05) in the different 
comparisons is detailed in Table 1. Venn diagram of the different comparisons revealed an 
intersection of 227 common dysregulated transcripts (containing 186 genes) in the three 
genodermatoses (Fig. 1b). Interestingly, all these transcripts (i.e. 129 upregulated and 98 
downregulated) showed not only the same expression pattern (Fig. 1c), but also an impressive 
positive correlation between the fold changes (Fig. 1d). This suggests that the common 
expression profile may have a similar phenotypic impact on the three diseases. 
Common expression patterns are best understood through the examination of enriched 
GO terms (26) and KEGG pathways (27). This approach provides an undirected method to 
highlight those biological mechanisms that could be potentially relevant to the diseases. The 
output of this enrichment analysis is a list of pathways and/or ontologies that involves a 
statistically significant number of dysregulated genes, associated to the same biological 
mechanism (Fig. 2, Table S4). Enriched GO terms for all the diseases point towards an 
abnormal relationship between the cell and its stroma. This suggests that the contribution of 
dermal fibroblasts to the disease lies in the altered response they exert on the surrounding 
microenvironment. The dysregulated genes were significantly associated with extracellular 
matrix and cell periphery (cellular component). Furthermore, glycosaminoglycan binding, 
sulfur compound binding and heparin binding - which point towards ECM components - are 
overrepresented (molecular function). Apart from these terms, an altered activity of 
transcription factors is also noticeable, presumably associated to the observed differences in 
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gene transcription. KEGG pathway analysis identified common alterations in PI3K-Akt 
signalling, chemokine repertoire and two cancer-related pathways (highlighted terms in Table 
S4). 
To gain a deeper insight into the altered mechanisms, we employed the web-tool 
Hipathia (http://hipathia.babelomics.org) to decompose KEGG pathways into signalling 
circuits, by transforming gene expression profiles into signal transduction activity profiles 
(23). We found 42 overlapping circuits in the three genodermatoses when comparing versus 
controls (Fig. S1a), with effectors associated to cell proliferation (AREG, MAPK8), TGF-β 
signalling (PITX2) and ECM-cell interactions (PLAU, MAP3K4) (highlighted terms in Table 
S5). A particular example of these circuits includes an activation of BCL2 - as effector 
molecule of anti-apoptotic effect - initiated in multiple overexpressed nodes and propagated 
through the PI3K-Akt pathway (Fig. S1b). 
To identify functional associations between the 186 differentially expressed genes 
STRING database (24) was used to generate PPI networks. The enrichment PPI p-value 
(0.00126) indicates that the commonly altered genes do not represent a randomly scattered set 
of proteins, but a meaningfully connected set of genes in accordance with its biological 
functions. Three major clusters (A, B and C) of proteins were detected (Fig. 3). Cluster A 
includes a group of proteins, mostly downregulated, involved in signalling pathways and 
signal transduction (e.g. JAK3, PTK2B and PRKCQ). Interestingly, this cluster also contains 
the angiotensin II receptor (AGTR1, upregulated), a target of recent anti-fibrotic therapy 
tested in RDEB (28), and the antioxidant enzyme extracellular superoxide dismutase (SOD3, 
downregulated), previously proposed as repressor molecule of skin inflammation (29). 
Cluster B is formed predominantly by a group of transcription factors (TF) (e.g. PITX2, a 
procollagen lysyl hydroxylase TF). Cluster C is represented by matrisome and matrisome-
associated genes (http://matrisomeproject.mit.edu) (30), implicated in the stabilization, 
deposition and remodelling of the ECM (e.g. TGFBI, FN1, TNC and POSTN). Among the 
minor-clustered nodes, downregulation of ALDH1A1 gene received our attention. This gene 
encodes an antioxidant enzyme related with UV-protection against oxidative stress (31) and 
is repressed by TGF-β (32). In our analysis, ALDH1A1 is one of the most significant 
underexpressed genes in the three diseases.  
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Validation of altered gene expression 
Given the importance of the extracellular component – evidenced by enriched GO 
terms and KEGG pathways - we took advantage of the STRING PPI and chose several 
proteins of Cluster C for validation by western blot (Fig. 4). In this analysis we included 
additional patient and control samples not used for RNA-Seq (Table S1b). In accordance with 
transcriptomic data, fibulin-1, transglutaminase-2 (TG2) and ALDH1A1 were 
underexpressed in the diseases; while expression of tenascin-C, periostin and TGFBI were 
increased. In addition to the changes observed in these markers, we found high levels of α-
sma in all genodermatoses fibroblasts confirming their activated phenotype (data not shown). 
Variability in protein expression levels in individual fibroblasts was observed, however, there 
was no evident pattern associated with body sites origin or age of donors. Abnormal 
expression of some of these proteins have been previously described in RDEB fibroblasts 
(33), but not the periostin overexpression. Thus, we decided to study their expression by 
immunofluorescence in available skin biopsy sections from RDEB and KS patients. The 
analysis showed a degree and pattern of overexpression similar to tenascin-C, used as 
positive control (Fig. 5).  
 
Identification of serum periostin as a novel biomarker in RDEB 
Increased levels of circulating periostin have been shown in several non-inherited 
fibrotic conditions including cancer (34,35). Considering the overexpression of periostin seen 
in vitro and in situ, we subsequently searched for periostin in available serum samples of 
RDEB patients and healthy donors. Consistently with the validation results, circulating 
periostin concentration were remarkably higher in RDEB patients (65,69ng/ml ± 14.75 SEM; 
n=16) compared to controls (3.72ng/ml ± 0.33 SEM; n=10) (p-value=0.0008; Fig. 6). This 
result suggests that periostin may represent a potential biomarker in RDEB. 
 
Discussion 
Here we conducted a global gene expression analysis of dermal fibroblasts - isolated 
from uninvolved skin areas of XPC, KS and RDEB patients - with the goal of elucidating 
overlapped pathomechanisms in these cancer-prone genodermatoses. Despite each disease’s 
gene expression singularities, our study allowed to identify a common signature of 227 
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transcripts and 4 KEGG pathways differentially expressed against healthy controls. Our 
different bioinformatic analyses revealed the presence of three major determinants of an 
activated fibroblast phenotype, namely: increased cell survival, altered TGF-ß signalling, and 
abnormal extracellular matrix remodelling (36,37). It is known that fibroblasts become 
activated when detect adverse cues from their surroundings - e.g. inflammation, mechanical 
trauma, TGF-ß, oxidative stress - and acquire a proliferative phenotype characterized by 
aberrant secretion of ECM molecules (38). Normally, activated fibroblasts return to their 
original state when the injury is resolved, through reprogramming or apoptosis (39). 
However, if the insult becomes chronic, fibroblasts become irreversibly active, just as it 
occurs in CAFs and fibrosis-associated fibroblasts (FAFs) (40).   
The pathway inference analysis highlighted several nodes involving PI3K-Akt 
signalling activation, ultimately triggering anti-apoptotic and hyperproliferative stimuli via 
BCL2 effector protein. Earlier studies on RDEB have also shown that increased PI3K-Akt 
signalling mediates cell survival and cSCC development. Indeed, it was proposed as one 
pharmacological target to prevent disease progression (41). On the other hand, ontologies and 
categories referred to an altered activity of the cellular exterior, resulting in altered 
production of chemokine repertoire and abnormal expression of matrisome and matrisome-
associated genes. The involvement of aberrantly expressed ECM proteins (e.g. tenascin-C, 
fibulin-1, transglutaminase-2, and TGFBI) was previously associated to loss of C7 (33,42). 
Overexpression of tenascin-C and TGF-β activation has also been shown in KS fibroblasts 
(14). To our knowledge, abnormal expression of periostin has not yet been reported in non-
tumoral XPC, KS or RDEB fibroblasts, but was recently shown in RDEB-cSCC biopsies 
(43). Periostin and tenascin-C are induced by skin damage, promoting the activation of 
fibroblasts to repair the wound. Their overexpression has been linked to pathogenic roles in 
chronic inflammation, fibrosis and cancer (34,44,45). Different studies have shown that 
elevated levels of serum periostin are associated with progression and disease severity in 
pulmonary fibrosis (46), colorectal cancer (47,48) and systemic sclerosis (49). Our workflow 
from RNA-Seq to validation at protein level allowed us to disclose periostin as a possible 
systemic biomarker, at least in RDEB (due to sample availability). Currently, several 
experimental anti-fibrotic therapies are under investigation for this disease (28). Considering 
the paucity of available minimally invasive biomarkers to assess treatment efficacy, 
circulating periostin may be a useful molecule to consider. Further studies will be necessary 
to extend these results to XPC and KS. 
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A general inferred notion from previous studies was that causal defects, such as loss 
of C7 or kindlin-1, could be accounted responsible for the abnormal ECM expression in 
RDEB and KS dermal fibroblasts (14,50,51). However, without excluding a triggering effect 
due to the primary deficiencies, our results challenge the view of a direct genetic cause-
driven effect. Rather, they stand for the existence of a shared injury-responsive event able to 
transduce the primary defect into epigenetic changes, leading to an activated phenotype (Fig. 
7). A likely candidate appears to be TGF-β since a large proportion of the common 
dysregulated genes (e.g. TNC, POSTN, FN1, TGFBI, and ALDH1A1) are modulated by this 
factor. Another possible candidate, already shown in XPC and KS (10,52–54), is oxidative 
stress which could be able, by itself or through their interaction with TGFβ, to trigger 
fibroblasts activation and ECM accumulation (55,56). In this context, downregulation of 
ALDH1A1 and SOD3 genes encoding for antioxidant enzymes could facilitate oxidative 
stress-induced damage. Similar expression changes in ALDH1A1 were recently described as 
part of the myofibroblast-specific expression profile in mouse skin wounds (57). In fact, an 
in-silico comparison of our 186 dysregulated genes disclosed 41 overlapping genes included 
in the transcriptomic signature of mouse wound myofibroblasts. Overexpression of POSTN 
and TNC, stand out among these 41 genes (Fig. S2). 
The examination of the exclusive transcriptional features of each disease may also 
offer interesting results, concerning the differential characteristics of each condition. 
However, these specific expression changes have not been the focus of this study and should 
be considered separately. All in all, the common genetic signature in fibroblasts of the three 
genodermatoses shares some similarities with that found in myofibroblasts (57), wound-
activated fibroblasts and cutaneous CAFs (11). The common mechanisms of the three 
diseases would allow considering the use of symptom-relief therapies currently tested in 
RDEB, also in XPC and KS. In addition, the new elucidated molecular targets, such as those 
involved in a derangement of the oxidative state, could be subject to novel pharmacological 
approaches.  
 
 
 
 
A
cc
ep
te
d 
A
rt
ic
le
References 
1.  DeStefano GM, Christiano AM. The Genetics of Human Skin Disease. Cold Spring 
Harb Perspect Med. 2014 Oct 1;4(10):a015172–a015172.  
2.  Fine J-D, Bruckner-Tuderman L, Eady RAJ, Bauer EA, Bauer JW, Has C, et al. 
Inherited epidermolysis bullosa: Updated recommendations on diagnosis and 
classification. J Am Acad Dermatol. 2014 Jun;70(6):1103–26.  
3.  Lotem M, Raben M, Zeltser R, Landau M, Sela M, Wygoda M, et al. Kindler 
syndrome complicated by squamous cell carcinoma of the hard palate: successful 
treatment with high-dose radiation therapy and granulocyte-macrophage colony-
stimulating factor. Br J Dermatol. 2001 Jun;144(6):1284–6.  
4.  Jobard F, Bouadjar B, Caux F, Hadj-Rabia S, Has C, Matsuda F, et al. Identification of 
mutations in a new gene encoding a FERM family protein with a pleckstrin homology 
domain in Kindler syndrome. Hum Mol Genet. 2003 Apr 15;12(8):925–35.  
5.  Siegel DH, Ashton GHS, Penagos HG, Lee J V., Feiler HS, Wilhelmsen KC, et al. 
Loss of Kindlin-1, a Human Homolog of the Caenorhabditis elegans Actin–
Extracellular-Matrix Linker Protein UNC-112, Causes Kindler Syndrome. Am J Hum 
Genet. 2003 Jul;73(1):174–87.  
6.  Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and 
neurologic abnormalities in 830 published cases. Arch Dermatol. 1987 
Feb;123(2):241–50.  
7.  DiGiovanna JJ, Kraemer KH. Shining a Light on Xeroderma Pigmentosum. J Invest 
Dermatol. 2012 Mar;132(3):785–96.  
8.  Rezvani HR, Kim AL, Rossignol R, Ali N, Daly M, Mahfouf W, et al. XPC silencing 
in normal human keratinocytes triggers metabolic alterations that drive the formation 
of squamous cell carcinomas. J Clin Invest. 2011 Jan 4;121(1):195–211.  
9.  Breitenbach JS, Rinnerthaler M, Trost A, Weber M, Klausegger A, Gruber C, et al. 
Transcriptome and ultrastructural changes in dystrophic Epidermolysis bullosa 
resemble skin aging. Aging (Albany NY). 2015;7(6):389–411.  
10.  Maier K, He Y, Wölfle U, Esser PR, Brummer T, Schempp C, et al. UV-B-induced 
cutaneous inflammation and prospects for antioxidant treatment in Kindler syndrome. 
Hum Mol Genet. 2016;25(24):5339–52.  
11.  Ng Y-Z, Pourreyron C, Salas-Alanis JC, Dayal JHS, Cepeda-Valdes R, Yan W, et al. 
Fibroblast-Derived Dermal Matrix Drives Development of Aggressive Cutaneous 
Squamous Cell Carcinoma in Patients with Recessive Dystrophic Epidermolysis 
Bullosa. Cancer Res. 2012;72(14):3522–34.  
12.  Bernerd F, Asselineau D, Vioux C, Chevallier-Lagente O, Bouadjar B, Sarasin A, et al. 
Clues to epidermal cancer proneness revealed by reconstruction of DNA repair-
deficient xeroderma pigmentosum skin in vitro. Proc Natl Acad Sci U S A. 2001 Jul 
3;98(14):7817–22.  
13.  Fréchet M, Warrick E, Vioux C, Chevallier O, Spatz A, Benhamou S, et al. 
A
cc
ep
te
d 
A
rt
ic
le
Overexpression of matrix metalloproteinase 1 in dermal fibroblasts from DNA repair-
deficient/cancer-prone xeroderma pigmentosum group C patients. Oncogene. 2008 Sep 
12;27(39):5223–32.  
14.  Heinemann A, He Y, Zimina E, Boerries M, Busch H, Chmel N, et al. Induction of 
phenotype modifying cytokines by FERMT1 mutations. Hum Mutat. 2011 
Apr;32(4):397–406.  
15.  Zamarrón A, García M, Del Río M, Larcher F, Juarranz Á. Effects of photodynamic 
therapy on dermal fibroblasts from xeroderma pigmentosum and Gorlin-Goltz 
syndrome patients. Oncotarget. 2017 Sep 29;8(44):77385–99.  
16.  Meana A, Iglesias J, Del Rio M, Larcher F, Madrigal B, Fresno M., et al. Large surface 
of cultured human epithelium obtained on a dermal matrix based on live fibroblast-
containing fibrin gels. Burns. 1998 Nov 1;24(7):621–30.  
17.  Robinson MD, Oshlack A. A scaling normalization method for differential expression 
analysis of RNA-seq data. Genome Biol. 2010;11(3):R25.  
18.  Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data 
using empirical Bayes methods. Biostatistics. 2007 Jan 1;8(1):118–27.  
19.  Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for 
differential expression analysis of digital gene expression data. Bioinformatics. 2010 
Jan 1;26(1):139–40.  
20.  Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and 
Powerful Approach to Multiple Testing. Vol. 57, Journal of the Royal Statistical 
Society. Series B (Methodological). WileyRoyal Statistical Society; 1995. p. 289–300.  
21.  Alonso R, Salavert F, Garcia-Garcia F, Carbonell-Caballero J, Bleda M, Garcia-
Alonso L, et al. Babelomics 5.0: functional interpretation for new generations of 
genomic data. Nucleic Acids Res. 2015 Jul 1;43(W1):W117-21.  
22.  Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths 
toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 
2009 Jan;37(1):1–13.  
23.  Hidalgo MR, Cubuk C, Amadoz A, Salavert F, Carbonell-Caballero J, Dopazo J. High 
throughput estimation of functional cell activities reveals disease mechanisms and 
predicts relevant clinical outcomes. Oncotarget. 2017 Jan 17;8(3):5160–78.  
24.  Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. 
STRING v10: protein–protein interaction networks, integrated over the tree of life. 
Nucleic Acids Res. 2015 Jan 28;43(D1):D447–52.  
25.  Escámez MJ, García M, Cuadrado-Corrales N, Llames SG, Charlesworth A, De Luca 
N, et al. The first COL7A1 mutation survey in a large Spanish dystrophic 
epidermolysis bullosa cohort: c.6527insC disclosed as an unusually recurrent mutation. 
Br J Dermatol. 2010 Apr;163(1):155–61.  
26.  Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene 
Ontology: tool for the unification of biology. Nat Genet. 2000 May;25(1):25–9.  
A
cc
ep
te
d 
A
rt
ic
le
27.  Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and 
interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012 Jan 
1;40(D1):D109–14.  
28.  Nyström A, Thriene K, Mittapalli V, Kern JS, Kiritsi D, Dengjel J, et al. Losartan 
ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms. 
EMBO Mol Med. 2015;7(9):1211–28.  
29.  Kwon M-J, Kim B, Lee YS, Kim T-Y. Role of superoxide dismutase 3 in skin 
inflammation. J Dermatol Sci. 2012 Aug;67(2):81–7.  
30.  Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular 
matrix: Tools and insights for the “omics” era. Matrix Biol. 2016 Jan;49:10–24.  
31.  Lassen N, Bateman JB, Estey T, Kuszak JR, Nees DW, Piatigorsky J, et al. Multiple 
and Additive Functions of ALDH3A1 and ALDH1A1. J Biol Chem. 2007 Aug 
31;282(35):25668–76.  
32.  Hoshino Y, Nishida J, Katsuno Y, Koinuma D, Aoki T, Kokudo N, et al. Smad4 
Decreases the Population of Pancreatic Cancer–Initiating Cells through Transcriptional 
Repression of ALDH1A1. Am J Pathol. 2015 May;185(5):1457–70.  
33.  Küttner V, MacK C, Rigbolt KTG, Kern JS, Schilling O, Busch H, et al. Global 
remodelling of cellular microenvironment due to loss of collagen VII. Mol Syst Biol. 
2013;9(657):1–14.  
34.  Yamaguchi Y. Periostin in Skin Tissue Skin-Related Diseases. Allergol Int. 
2014;63(2):161–70.  
35.  González-González L, Alonso J. Periostin: A Matricellular Protein With Multiple 
Functions in Cancer Development and Progression. Front Oncol. 2018 Jun 12;8:225.  
36.  Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C, Brown RA. Myofibroblasts and 
mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol. 2002 
May 1;3(5):349–63.  
37.  Parsonage G, Filer AD, Haworth O, Nash GB, Rainger GE, Salmon M, et al. A stromal 
address code defined by fibroblasts. Trends Immunol. 2005 Mar;26(3):150–6.  
38.  Vong S, Kalluri R. The Role of Stromal Myofibroblast and Extracellular Matrix in 
Tumor Angiogenesis. Genes Cancer. 2011 Dec 1;2(12):1139–45.  
39.  Micallef L, Vedrenne N, Billet F, Coulomb B, Darby IA, Desmoulière A. The 
myofibroblast, multiple origins for major roles in normal and pathological tissue 
repair. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S5.  
40.  Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 
2016;16(9):582–98.  
41.  Mittapalli VR, Madl J, Lï¿½ffek S, Kiritsi D, Kern JS, Rï¿½mer W, et al. Injury-
driven stiffening of the dermis expedites skin carcinoma progression. Cancer Res. 
2016;76(4):940–51.  
42.  Küttner V, Mack C, Gretzmeier C, Bruckner-Tuderman L, Dengjel J. Loss of collagen 
A
cc
ep
te
d 
A
rt
ic
le
VII is associated with reduced transglutaminase 2 abundance and activity. J Invest 
Dermatol. 2014;134(9):2381–9.  
43.  Föll MC, Fahrner M, Gretzmeier C, Thoma K, Biniossek ML, Kiritsi D, et al. 
Identification of tissue damage, extracellular matrix remodeling and bacterial 
challenge as common mechanisms associated with high-risk cutaneous squamous cell 
carcinomas. Matrix Biol. 2018;66(2018):1–21.  
44.  Midwood KS, Chiquet M, Tucker RP, Orend G. Tenascin-C at a glance. J Cell Sci. 
2016 Dec 1;129(23):4321–7.  
45.  Yang L, Serada S, Fujimoto M, Terao M, Kotobuki Y, Kitaba S, et al. Periostin 
Facilitates Skin Sclerosis via PI3K/Akt Dependent Mechanism in a Mouse Model of 
Scleroderma. Rossini A, editor. PLoS One. 2012 Jul 24;7(7):e41994.  
46.  Naik PK, Bozyk PD, Bentley JK, Popova AP, Birch CM, Wilke CA, et al. Periostin 
promotes fibrosis and predicts progression in patients with idiopathic pulmonary 
fibrosis. Am J Physiol Lung Cell Mol Physiol. 2012 Dec 15;303(12):L1046-56.  
47.  Ben Q-W, Zhao Z, Ge S-F, Zhou J, Yuan F, Yuan Y-Z. Circulating levels of periostin 
may help identify patients with more aggressive colorectal cancer. Int J Oncol. 2009 
Mar;34(3):821–8.  
48.  Dong D, Zhang L, Jia L, Ji W, Wang Z, Ren L, et al. Identification of Serum Periostin 
as a Potential Diagnostic and Prognostic Marker for Colorectal Cancer. Clin Lab. 2018 
Jun 1;64(6):973–81.  
49.  Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z, et al. Serum 
periostin levels are correlated with progressive skin sclerosis in patients with systemic 
sclerosis. Br J Dermatol. 2013 Apr;168(4):717–25.  
50.  Cianfarani F, Zambruno G, Castiglia D, Odorisio T. Pathomechanisms of Altered 
Wound Healing in Recessive Dystrophic Epidermolysis Bullosa. Am J Pathol. 
2017;187(7):1445–53.  
51.  Bruckner-Tuderman L, Has C. Disorders of the cutaneous basement membrane zone—
The paradigm of epidermolysis bullosa. Matrix Biol. 2014 Jan;33:29–34.  
52.  Zapatero-Solana E, García-Giménez JL, Guerrero-Aspizua S, García M, Toll A, 
Baselga E, et al. Oxidative stress and mitochondrial dysfunction in Kindler syndrome. 
Orphanet J Rare Dis. 2014 Dec 21;9(1):211.  
53.  Emmert H, Patel H, Brunton VG. Kindlin-1 protects cells from oxidative damage 
through activation of ERK signalling. Free Radic Biol Med. 2017;108(May):896–903.  
54.  Hosseini M, Ezzedine K, Taieb A, Rezvani HR. Oxidative and Energy Metabolism as 
Potential Clues for Clinical Heterogeneity in Nucleotide Excision Repair Disorders. J 
Invest Dermatol. 2015 Feb;135(2):341–51.  
55.  Liu RM, Desai LP. Reciprocal regulation of TGF-β and reactive oxygen species: A 
perverse cycle for fibrosis. Redox Biol. 2015;6:565–77.  
56.  Richter K, Kietzmann T. Reactive oxygen species and fibrosis: further evidence of a 
significant liaison. Cell Tissue Res. 2016 Sep 27;365(3):591–605.  
A
cc
ep
te
d 
A
rt
ic
le
57.  Bergmeier V, Etich J, Pitzler L, Frie C, Koch M, Fischer M, et al. Identification of a 
myofibroblast-specific expression signature in skin wounds. Matrix Biol. 2018;65:59–
74.  
 
  
A
cc
ep
te
d 
A
rt
ic
le
TABLES 
 
Table 1. Number of genes differentially expressed in each genodermatosis versus healthy 
controls. 
Differentially expressed genes 
Comparison Under-expressed* Over-expressed* Total DE 
RDEB vs Ctrl 516 327 843 
KS vs Ctrl 196 180 376 
XPC vs Ctrl 523 509 1032 
  
* Under- or over-expressed genes in the diseases.  
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FIGURES LEGENDS 
 
Fig. 1. Differential gene expression profile. (a) PCA-plot represents the global distribution 
of each sequenced sample, after data processing and normalization. Disease samples tend to 
group together and distantly from the controls. (b) An overlapping set of 227 transcripts, were 
commonly dysregulated in all the diseases (Venn diagram). (c) Heatmap of the normalized 
expression of the 227 transcripts (detailed in Table S3d) is shown (red: upregulated, green: 
downregulated in the disease). (d) Linear regression of fold changes of the 227 transcripts 
(blue dots) shows an impressive positive correlation (R2=0.895). Axes indicate fold change 
values (logarithmic scale).  
Fig. 2. Enrichment analysis of differentially expressed genes. Within the specific 
alterations of each disease, enriched GO terms highlight common abnormalities in the three 
genodermatoses with respect to cell periphery, extracellular matrix and activity of 
transcription factors. KEGG pathways reveal enriched categories related with cancer, PI3K-
Akt and chemokine signalling. The highest ranked categories in each disease are shown 
according to the p-value and percentage of genes. 
Fig. 3. Protein-protein interaction network of the common dysregulated genes. The three 
largest connected components, labelled as “Cluster A, B and C”, represent a cluster of highly-
connected, biologically related proteins. Node colour is graded according to the average fold 
change (red: upregulated, green: downregulated in the disease). Edge width is proportional to 
STRING interaction score, which represents the confidence for that interaction. Groups of 
potentially interactive proteins with fewer nodes are shown below the main clusters. Proteins 
without interactions are not shown. The average node degree is 0.387 and the average local 
clustering coefficient is 0.158.  
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Fig. 4. Western blot validation of relevant genes. Immunoblot analysis of fibroblast cell-
lysates confirm the high expression of tenascin-C, periostin and TGFBI, together with an 
underexpression of TG2, ALDH1A1 and fibulin-1 in samples from RDEB, XPC and KS 
patients. GAPDH was used as loading control. Samples not included in the RNA-Seq are 
indicated by an asterisk (*).  
Fig. 5. Immunofluorescence in situ validation of tenascin-C and periostin. Skin biopsies 
sections from RDEB, KS and healthy controls were stained for (a) tenascin-C and (b) 
periostin. Quantitation of fluorescence intensity was measured on five non-overlapping 
microscopic fields per sample (ImageJ) and represented as mean staining intensity/area value 
+/- SD. The data were analysed by Students t-test *p<0.05; ** p<0.01. 
Fig. 6. Circulating periostin levels in RDEB patients. Serum periostin concentration was 
significantly higher in RDEB patients (65.69ng/ml ± 14.75 SEM; n=16) compared to donor 
controls (3.72ng/ml ± 0.33 SEM; n=10). Two independent experiments were performed for 
each patient sample and controls. ***p-value=0.0008. 
Fig.7. Model of the common pathomechanism suggested for RDEB, XPC and KS. 
Genodermatoses fibroblasts respond similarly to tissue injury and inflammation. These 
persistent stimuli may converge into the activation of TGF-β signalling and oxidative 
imbalance, which lead the overexpression of ECM proteins (e.g. TNC, POSTN and FN1) and 
the reduction of antioxidant enzymes (e.g. ALDH1A1 and SOD3). Reciprocal regulation 
between TGF-β and ROS allows the acquisition of an activated and synthetic fibroblast 
phenotype and may promote the disease progression.  
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Supporting information 
 
Fig. S1. Pathway activity analysis. (a) Venn diagram, derived from the Hipathia analysis, 
reveals an overlapping set of 42 signalling circuits common to the three genodermatoses 
(detailed in Table S5). (b) Representation of the BCL2-mediated apoptosis inhibition circuit. 
The increased activity of BCL2 (final effector of the pathway) is initiated mainly by the 
overexpression of HRAS and RAC1. This leads to the activation of PI3K-Akt signalling 
which, together with the overexpression of YWHAQ, inactivates the action of BAD (a 
repressor of BCL2), thus preventing cell apoptosis. 
Fig. S2. Venn Diagram of dysregulated genes in myofibroblasts and genodermatoses 
fibroblasts. The comparison revealed an overlap of 41 altered genes, including POSTN, TNC 
and ALDH1A1. 
Table S1. Patient information. Age, sex and gene/protein mutation of all patient and control 
samples used in (a) RNA-Seq and (b) validation analysis.  
Table S2. Normalized RNA-Seq counts for all genes and all samples.  
Table S3. Differentially expressed genes (FDR<0.05). (a) RDEB vs Ctrl; (b) XPC vs Ctrl; 
(c) KS vs Ctrl. 
Table S4. Gene Ontology and KEGG enrichment analysis. GO terms (cellular 
components and molecular functions) and KEGG enriched pathways (p-value <0.1) obtained 
from genes differentially expressed in (a) RDEB vs Ctrl; (b) KS vs Ctrl; (c) XPC vs Ctrl.  
Table S5. Pathway activity analysis. Signalling enriched Hipathia circuits (adjusted p-
value<0.05) obtained from genes differentially expressed in (a) RDEB vs Ctrl; (b) KS vs Ctrl; 
(c) XPC vs Ctrl. In orange, circuits altered in the three diseases. 
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